Literature DB >> 14742283

Fraction of cases of acquired immunodeficiency syndrome prevented by the interactions of identified restriction gene variants.

M J Silverberg1, M W Smith, J S Chmiel, R Detels, J B Margolick, C R Rinaldo, S J O'Brien, A Muñoz.   

Abstract

Previous research has demonstrated isolated effects of host genetic factors on the progression of human immunodeficiency virus type 1 (HIV-1) infection. In this paper, the authors present a novel use of multivariable methods for estimating the prevented fraction of acquired immunodeficiency syndrome (AIDS) cases attributable to six restriction genes after accounting for their epidemiologic interactions. The methods presented will never yield a prevented fraction above 1. The study population consisted of a well-characterized cohort of 525 US men with HIV-1 seroconversion documented during follow-up (1984-1996). On the basis of a regression tree approach using a Cox proportional hazards model for times to clinical AIDS, the combinations of genes associated with the greatest protection, relative to the lack of a protective genotype, consisted of: 1) C-C chemokine receptor 5 (CCR5)-Delta 32 and C-C chemokine receptor 2 (CCR2)-64I (relative hazard = 0.44); 2) interleukin 10 (IL10)-+/+ in combination with CCR5-Delta 32 or CCR2-64I (relative hazard = 0.45); and 3) IL10-+/+ in combination with stromal-derived factor (SDF1)-3 'A and CCR5 promoter P1/approximately P1 (relative hazard = 0.37). Overall, 30% of potential AIDS cases were prevented by the observed combinations of restriction genes (95% confidence interval: 7, 47). However, the combined effect was confined to the first 4 years following HIV-1 seroconversion. Additional research is needed to identify AIDS restriction genes with stronger and long-lasting protection to better characterize the genetic epidemiology of HIV-1.

Entities:  

Mesh:

Year:  2004        PMID: 14742283     DOI: 10.1093/aje/kwh036

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  6 in total

1.  Update on the Virologic and Immunologic Response to Highly Active Antiretroviral Therapy.

Authors:  Lisa P. Jacobson; John P. Phair; Traci E. Yamashita
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

Review 2.  Virologic and immunologic response to highly active antiretroviral therapy.

Authors:  Lisa P Jacobson; John P Phair; Traci E Yamashita
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

3.  Attributable fraction functions for censored event times.

Authors:  Li Chen; D Y Lin; Donglin Zeng
Journal:  Biometrika       Date:  2010-05-28       Impact factor: 2.445

4.  Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring.

Authors:  Xiuhong Li; Haitao Chu; Joel E Gallant; Donald R Hoover; Wendy J Mack; Joan S Chmiel; Alvaro Muñoz
Journal:  J Epidemiol Community Health       Date:  2006-09       Impact factor: 3.710

5.  Survival attributable to an exposure.

Authors:  Christopher Cox; Haitao Chu; Alvaro Muñoz
Journal:  Stat Med       Date:  2009-11-20       Impact factor: 2.373

6.  Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality.

Authors:  Mohammadreza Bozorgmanesh; Farzad Hadaegh; Farhad Sheikholeslami; Arash Ghanbarian; Fereidoun Azizi
Journal:  Cardiovasc Diabetol       Date:  2012-06-15       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.